Literature DB >> 16611145

Structure- and fragment-based approaches to protease inhibition.

Sherida L Johnson1, Maurizio Pellecchia.   

Abstract

Proteases are essential enzymes which regulate physiological processes such as inflammation, infection, fertilization, allergic reactions, cell growth and death, blood clotting, tumor growth and bone remodeling. The protease family consists of six major classes of enzymes which are aspartic-, serine-, cysteine-, threonine-, glutamic-, and metallo-proteases, all which are implicated in disease propagation. Therefore, protease inhibitors have been of great interest as possible targets for the development of novel therapies. Although, many protease inhibitors have followed a structural design based on either a peptidic or peptidomimetic backbone, other chemical scaffolds have recently emerged. Utilizing structure- and fragment-based design guided by X-ray crystallography, NMR spectroscopy, computational and/or extended tethering approaches, potential non-peptidic therapeutic agents could be identified. In this review, we will report on the recent developments of nonpeptidic cysteine- and metallo- protease inhibitors, focusing on their design by using such strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611145     DOI: 10.2174/156802606776287072

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  12 in total

1.  Thioamide hydroxypyrothiones supersede amide hydroxypyrothiones in potency against anthrax lethal factor.

Authors:  Arpita Agrawal; César Augusto F de Oliveira; Yuhui Cheng; Jennifer A Jacobsen; J Andrew McCammon; Seth M Cohen
Journal:  J Med Chem       Date:  2009-02-26       Impact factor: 7.446

Review 2.  New approaches for dissecting protease functions to improve probe development and drug discovery.

Authors:  Edgar Deu; Martijn Verdoes; Matthew Bogyo
Journal:  Nat Struct Mol Biol       Date:  2012-01-05       Impact factor: 15.369

3.  Purification and characterization of a newly serine protease inhibitor from Rhamnus frangula with potential for use as therapeutic drug.

Authors:  Abir Ben Bacha; Ikram Jemel; Nadine M S Moubayed; Imen Ben Abdelmalek
Journal:  3 Biotech       Date:  2017-06-08       Impact factor: 2.406

4.  A high-throughput screening approach to anthrax lethal factor inhibition.

Authors:  Sherida L Johnson; Li-Hsing Chen; Maurizio Pellecchia
Journal:  Bioorg Chem       Date:  2007-02-22       Impact factor: 5.275

5.  Acid ceramidase as a therapeutic target in metastatic prostate cancer.

Authors:  Luz Camacho; Oscar Meca-Cortés; José Luis Abad; Simón García; Nuria Rubio; Alba Díaz; Toni Celià-Terrassa; Francesca Cingolani; Raquel Bermudo; Pedro L Fernández; Jerónimo Blanco; Antonio Delgado; Josefina Casas; Gemma Fabriàs; Timothy M Thomson
Journal:  J Lipid Res       Date:  2013-02-19       Impact factor: 5.922

6.  Chelator fragment libraries for targeting metalloproteinases.

Authors:  Arpita Agrawal; Sherida L Johnson; Jennifer A Jacobsen; Melissa T Miller; Li-Hsing Chen; Maurizio Pellecchia; Seth M Cohen
Journal:  ChemMedChem       Date:  2010-02-01       Impact factor: 3.466

7.  Small-molecule inhibitors of lethal factor protease activity protect against anthrax infection.

Authors:  Mahtab Moayeri; Devorah Crown; Guan-Sheng Jiao; Seongjin Kim; Alan Johnson; Clinton Leysath; Stephen H Leppla
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

8.  Protease inhibitor from Moringa oleifera with potential for use as therapeutic drug and as seafood preservative.

Authors:  B Bijina; Sreeja Chellappan; Jissa G Krishna; Soorej M Basheer; K K Elyas; Ali H Bahkali; M Chandrasekaran
Journal:  Saudi J Biol Sci       Date:  2011-04-18       Impact factor: 4.219

9.  Structural basis of metallo-β-lactamase, serine-β-lactamase and penicillin-binding protein inhibition by cyclic boronates.

Authors:  Jürgen Brem; Ricky Cain; Samuel Cahill; Michael A McDonough; Ian J Clifton; Juan-Carlos Jiménez-Castellanos; Matthew B Avison; James Spencer; Colin W G Fishwick; Christopher J Schofield
Journal:  Nat Commun       Date:  2016-08-08       Impact factor: 14.919

10.  Computer-aided lead optimization: improved small-molecule inhibitor of the zinc endopeptidase of botulinum neurotoxin serotype A.

Authors:  Jing Tang; Jewn Giew Park; Charles B Millard; James J Schmidt; Yuan-Ping Pang
Journal:  PLoS One       Date:  2007-08-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.